It’s been one heck of a rout within the biotech sector this afternoon, and shares of Medivation Inc (NASDAQ:MDVN) have certainly joined in on the party. The stock is down The stock is down 11.96% or $4.87, hitting $35.86 per share. About 1.62M shares traded hands or 23.66% up from the average. MDVN has declined 30.99% since June 5, 2015 and is downtrending. It has underperformed the S&P500 by 26.30%.
From a total of 10 analysts covering Medivation Inc (NASDAQ:MDVN) stock, 6 rate it a “Buy”, 0 a “Sell”, and 4 a “Hold”. This means that 60% of the ratings are positive. The highest target price is $166 while the lowest target price is $40. The mean of all analyst targets is $82.18 which is 129.17% above today’s ($35.86) stock price. Medivation Inc was the topic of 20 analyst reports since July 31, 2015 according to the firm StockzIntelligence Inc. Maxim Group maintained shares on November 10 with a “Buy” rating. Brean Capital maintained shares with a”Buy” rating and a $142 target share price in their report from an August 10. UBS maintained MDVN stock in a recent report from November 6 with a “Buy” rating. Finally, Nomura initiated the stock with a “Buy” rating in a report they issued on a September 15.
The institutional sentiment increased to 3.17 in Q2 2015. It’s up 1.94, from 1.23 in 2015Q2. The ratio is positive, as 67 funds sold all their Medivation Inc shares they owned while 28 reduced their positions. 56 funds bought stakes while 245 increased their total positions. Institutions now own 263.87 million shares which is 259.35% more than the previous share count of 73.43 million in 2015Q2.
Knoll Capital Management Lp holds 79.35% of its total portfolio in Medivation Inc, equating to 4.40 million shares. Apis Capital Advisors Llc owns 93,500 shares representing 5.5% of their total US portfolio. Moreover, March Altus Capital Management Lp has 4.71% of their total portfolio invested in the company, equating to 18,794 shares. The New York-based Healthcor Management L.P. has a total of 4.55% of their portfolio invested in the stock. Bb Biotech Ag, a Switzerland-based fund reported 2.58 million shares owned.
Since March 2, 2015, the stock had 0 insider purchases, and 2 selling transactions for a total of $3.33 million in net activity. Machado Clarence Patrick sold 71,980 shares worth $3.05 million. Svoronos Dawn sold 3,100 shares worth $276,365. Bierly Rick sold 1,000 shares worth $130,000. Rhodes Jennifer J sold 1,390 shares worth $181,979. The insider Falberg Kathryn E bought 25,000 shares worth $2.94 million.
Medivation, Inc. is a biopharmaceutical company. The company has a market cap of $6.33 billion. The Firm is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. It has 22.93 P/E ratio. The Firm in collaboration with Astellas Pharma, Inc. has one commercial product, XTANDI capsules (XTANDI).